Last reviewed · How we verify
acute post-surgical hypoparathyroidism
Approved treatments
- Yorvipath · Ascendis Pharma Bone
Palopegteriparatide releases PTH(1-34) to maintain calcium and phosphate homeostasis through PTH1R.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- acute post-surgical hypoparathyroidism patent landscape — cliff calendar, originator estates, attackable patents
- acute post-surgical hypoparathyroidism treatment landscape brief
- acute post-surgical hypoparathyroidism treatment updates RSS
Frequently asked questions about acute post-surgical hypoparathyroidism
What drugs treat acute post-surgical hypoparathyroidism?
Tracked treatments include Yorvipath.
What is the treatment for acute post-surgical hypoparathyroidism?
Standard treatment for acute post-surgical hypoparathyroidism includes Yorvipath. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: acute post-surgical hypoparathyroidism patent cliff · acute post-surgical hypoparathyroidism CI report
- Treatment: Yorvipath · Ascendis Pharma Bone
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing